Pharmacogenomic testing for antidepressants could help reduce the time and cost it takes to find the most effective medication for a patient, according to a new study. Scientists developed a ...

A special kind of genetic test that helps determine the best antidepressant for patients with moderate-to-severe depression could generate substantive health system savings and greatly improve patient ...

Enable more effective and targeted treatments that address unique needs for patients with pharmacogenomics. The traditional one-size-fits-all approach to medication has long been recognized as a ...

A special kind of genetic test that helps determine the best antidepressant for patients with moderate-to-severe depression could generate substantive health system savings and greatly improve patient ...

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer ...

Pharmacogenetic testing, which is used to classify how patients with major depressive disorder (MDD) metabolize medications, reduces adverse drug-gene interactions, new research shows. In a randomized ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window LAS VEGAS -- ...

New Orleans-based Ochsner Health was met with some uncertainty when it launched its pharmacogenomic program in March 2022 and became one of the first health systems to standardize genomic testing.

Rosalind Brown had blood clots in her lungs. For years, her doctors tried to get the dose of a blood thinner just right to prevent the risk of a heart attack or other life-threatening complications ...